This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

X-linked lymphoproliferative disease / XLP / Duncan diseaseX-연관 림프증식성 질환 (던컨병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D82.3 (Immunodeficiency following hereditary defective response to Epstein-Barr virus) | OMIM: 308240 (XLP1, SH2D1A) / 300635 (XLP2, XIAP) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsImmunodeficiency following hereditary defective response to Epstein-Barr virus, X-linked lymphoproliferative disease (XLP), Duncan disease, SH2D1A deficiency, SAP deficiency, XIAP deficiency (XLP2), X-linked lymphoproliferative syndrome
C. Adult onsetPossibility of first presenting in adulthood Low to moderate — if primary EBV infection did not occur in childhood or adolescence, it may first present in adulthood as fatal mononucleosis or HLH at the first EBV infection; in some XLP patients, hypogammaglobulinemia is first diagnosed in adulthood.
1. History1975 Purtilo et al. reported an EBV-associated fatal infection syndrome in boys of the Duncan family → X-linked immunodeficiency confirmed → SAP (SH2D1A) gene identified (1998) → XIAP/XLP2 discovered (2006).
2. CausesXLP1: SH2D1A gene (Xq25) variant → SAP protein deficiency → dysregulated activation of EBV-infected T/NK cells. XLP2: XIAP gene (Xq25) variant → impaired inhibition of cell death → excessive immune activation.
3. GeneticsX-linked recessive; SH2D1A (Xq25), XIAP (Xq25). Males affected; female carriers are asymptomatic, though autoimmune phenomena have rarely been reported in some. De novo variants possible.
4. General epidemiologyAbout 1:1,000,000 male births; several hundred cases worldwide. Very rare in Korea. Asymptomatic until EBV exposure, so likely underdiagnosed.
5. PathophysiologySAP deficiency → dysregulated cytotoxic response of CD8+ T/NK cells against EBV-infected B cells → unrestrained lymphoproliferation → HLH, lymphoma, immune exhaustion. XIAP deficiency → abnormal NF-κB signaling and regulation of cell death.
6. SymptomsAfter EBV infection: fatal infectious mononucleosis (FIM), hemophagocytic lymphohistiocytosis (HLH), malignant lymphoma (mainly B-cell NHL), hypogammaglobulinemia. In the EBV-uninfected state: asymptomatic or recurrent infections.
7. SignsFever, hepatosplenomegaly, lymphadenopathy; HLH: cytopenia in two or more lineages, hyperferritinemia, hypertriglyceridemia, elevated sCD25; abnormal EBV VCA/EA/EBNA antibody pattern; hemophagocytosis in bone marrow.
8. ScreeningBoys with a family history: SH2D1A/XIAP gene testing immediately after birth. Boys who developed HLH or fatal mononucleosis: XLP panel testing. Screening for SAP protein expression (flow cytometry).
9. DiagnosisSH2D1A/XIAP gene sequencing; SAP/XIAP protein expression (flow cytometry/Western blot); EBV serology/PCR; HLH criteria (HScore); bone marrow biopsy; NK cell function (degranulation assay).
10. TreatmentAt HLH onset: dexamethasone + etoposide (HLH-2004 protocol), rituximab (depletion of EBV+ B cells). Curative: HSCT. If not yet exposed to EBV, prophylactic IVIG and minimizing EBV exposure. XIAP deficiency: HSCT essential.
11. PrognosisAfter EBV infection, mortality is 70-100% without treatment. 5-year survival after HSCT is 70-80%. HSCT after HLH onset has lower survival. Early diagnosis and HSCT before EBV exposure is best.
12. PreventionGenetic counseling, genetic testing immediately after the birth of a boy; blocking EBV exposure (EBV-negative blood products); HSCT before EBV infection is the best prevention; regular IVIG administration.
13. ReferencesPurtilo DT et al. X-linked recessive progressive combined variable immunodeficiency … and 9 other papers

1. History

The history of X-linked lymphoproliferative disease (XLP) begins in 1975, when the American immunologist David T. Purtilo systematically described cases in which fatal infectious mononucleosis (FIM) developed after Epstein-Barr virus (EBV) infection in several male members of a family named Duncan. In a paper published in The Lancet, Purtilo reported that EBV infection in this family followed a fatal course rather than the self-limited disease seen in the general population, and proposed that this abnormal response resulted from a genetic predisposition linked to the X chromosome. The disease later also came to be called "Duncan disease" after the name of this family.

Through the 1970s and 1980s, the clinical spectrum of XLP gradually expanded. In addition to fatal infectious mononucleosis, hemophagocytic lymphohistiocytosis (HLH) after EBV infection, malignant B-cell lymphoma (especially Burkitt lymphoma-like), and acquired hypogammaglobulinemia arising after EBV infection were established as the main clinical triad of XLP. In 1987 Purtilo established the XLP Registry and began to accumulate international case data, through which important epidemiological data on the incidence, distribution of clinical phenotypes, and prognosis of this disease were accumulated.

The molecular genetic cause was elucidated in 1998, when several research groups simultaneously identified the causative gene SH2D1A (Src homology 2 domain-containing protein 1A) at Xq25. The protein encoded by SH2D1A was named SAP (SLAM-associated protein), and it was shown to bind SLAM (signaling lymphocyte activation molecule) family receptors and regulate activation of T cells and NK cells. The molecular mechanism of why SAP/SH2D1A deficiency specifically results in failure to regulate the immune response to EBV infection was elucidated in detail through the 2000s.

In 2006, a second gene causing a separate XLP phenotype, XIAP (X-linked inhibitor of apoptosis protein), was discovered and named XLP2. XLP2 patients are clinically similar to XLP1 but are distinguished by the fact that HLH occurs even in the EBV-uninfected state and inflammatory bowel disease (IBD) often accompanies it. XIAP is a protein essential for inhibiting cell death (apoptosis), and later studies have clarified how its deficiency links hyperactivation of immune cells with the mechanism that triggers HLH. XLP is currently classified as ICD-10 D82.3 and is used as a concept encompassing SH2D1A deficiency (XLP1) and XIAP deficiency (XLP2).

From the 2010s, HSCT was established as the only curative therapy for XLP, and large cohort studies demonstrated that early transplantation before EBV infection dramatically improves survival. It was also confirmed that rituximab contributes to the acute treatment of HLH by selectively eliminating EBV-positive B cells, which refined the treatment strategy.

2. Causes

The causes of XLP are divided into pathogenic variants of two genes located on the X chromosome. XLP1 is caused by variants of the SH2D1A gene (Xq25), and XLP2 is caused by variants of the XIAP (X-linked inhibitor of apoptosis) gene, adjacent at the same chromosomal location (Xq25). Because both diseases follow an X-linked recessive mode of inheritance, only males are clinically affected.

In XLP1, SAP (SLAM-associated protein), encoded by the SH2D1A gene, is a small adaptor protein consisting only of an SH2 domain and is expressed in T cells and NK cells. SAP binds to the immunoreceptor tyrosine-based switch motif (ITSM) in the cytoplasmic tails of SLAM family receptors such as SLAM (CD150), 2B4 (CD244), NTB-A (Ly108), and CRACC (CS1), and regulates signaling through these receptors. The 2B4 receptor signaling pathway of T cells (CD8+) and NK cells is key to eliminating EBV-infected B cells, but in SAP deficiency 2B4 signaling is instead converted to an inhibitory signal, so the cytotoxic capacity of T/NK cells against EBV-infected B cells is markedly reduced. As a result, EBV-infected B cells proliferate without limit.

In XLP2, XIAP (also called BIRC4) is an IAP (inhibitor of apoptosis protein) family protein that prevents cell death by directly inhibiting caspase-3, -7, and -9. In XIAP deficiency, immune cells, especially T cells and NK cells, become hypersensitive to activation-induced cell death, and abnormalities of NF-κB signaling and the NOD2 signaling pathway occur, causing an excessive inflammatory response and HLH. This mechanism explains why spontaneous HLH occurs in XLP2 patients even without EBV infection, and why IBD accompanies it.

Missense variants, nonsense variants, splicing variants, and small/large deletions have all been reported as SH2D1A variant types. In about 25-30% of patients with a clinical diagnosis of XLP1, no SH2D1A variant is detected, so a phenotype-genotype discordance exists. Various types of XIAP variants are also reported. Both genes are located at Xq25 and are adjacent but perform independent functions.

3. Genetics

XLP follows an X-linked recessive mode of inheritance. There are two causative genes. SH2D1A (signal transduction adaptor molecule, OMIM #300490) is located at Xq25 and consists of 4 exons. The SAP (SLAM-associated protein) produced by this gene is a small SH2-domain protein of 128 amino acids. XIAP (X-linked inhibitor of apoptosis, OMIM #300079) is located at Xq25 adjacent to SH2D1A and consists of 7 exons. The XIAP protein is a multifunctional protein of 497 amino acids with three BIR (baculovirus IAP repeat) domains and one RING domain.

Owing to the nature of X-linked recessive inheritance, only males are affected (hemizygous), and if the mother is a heterozygous carrier, her sons are affected with 50% probability. Female carriers are generally asymptomatic, but there are rare reports that, when X-chromosome inactivation (lyonization) is asymmetric, the abnormal X chromosome is expressed more and mild immune abnormalities may appear. Occurrence due to de novo variants is also reported, and in this case it occurs without family history, which can delay diagnosis.

SH2D1A variants are distributed throughout the SH2 domain, and missense variants that directly destroy the ITSM-binding ability of the SH2 domain are most common. They are reported sporadically across exons 1-4. XIAP variants are concentrated in the BIR domains or RING domain, and variants that abolish caspase-inhibiting ability are confirmed to be pathogenic. Variants are identified by whole-exome or NGS panel testing, and diagnostic accuracy can be increased by performing protein expression testing (SAP or XIAP, flow cytometry or Western blot) in parallel. Even when no variant is found, XLP can be diagnosed by clinical findings and protein expression testing.

The key points in genetic counseling are ① sons of a carrier mother are affected with 50% probability, ② all daughters of an affected male are carriers, ③ because the disease is asymptomatic during the period without EBV exposure, early genetic diagnosis is decisive for saving lives, and ④ prenatal diagnosis (CVS/amniocentesis) and PGT are technically possible.

4. General epidemiology

XLP is an extremely rare disease with an incidence of about 1-2 per 1 million male births worldwide. About 300-500 confirmed patients have been reported worldwide, and many of them were registered through the XLP Registry (established by David Purtilo) and the European Society for Immunodeficiencies registry (ESID). Following X-linked recessive inheritance, only males are clinically affected, and female carriers are mostly asymptomatic.

No differences in incidence by race or region have been reported, but the incidence may increase in populations with many consanguineous marriages if carrier frequency is high. It is very rare in Korea, and there are no official domestic epidemiological statistics. Because it is asymptomatic until EBV exposure, the actual number of prevalent patients is estimated to be higher than the number reported.

The age at clinical onset is directly tied to the timing of primary EBV infection. In most patients, the first clinical manifestation appears when EBV infection occurs in early childhood (2-10 years), and if not exposed to EBV, patients remain asymptomatic until adolescence or adulthood. The most common clinical phenotypes after EBV infection are HLH (about 30%), fatal infectious mononucleosis (about 25%), malignant lymphoma (about 30%), and hypogammaglobulinemia (about 30%), and multiple phenotypes may occur in a single patient. When not diagnosed before EBV exposure, the first EBV infection follows a fatal course, and a pattern of repeated deaths of male family members may raise suspicion. XLP2 (XIAP deficiency) accounts for about 15-20% of all XLP and has a high rate of EBV-uninfected HLH and accompanying IBD.

5. Pathophysiology

The core pathophysiology of XLP1 (SAP deficiency) arises from failure to regulate the cytotoxic response of T cells and NK cells against EBV-infected B cells. Normally, when EBV infects B cells, viral antigens are presented on MHC I molecules and EBV-specific CD8+ T cells (CTLs) eliminate the infected B cells, and cytotoxicity through the activating receptor 2B4 (CD244) of NK cells also contributes to this process. In addition, EBV-specific CD4+ T cells play a helper role, and in the long term the EBV-specific memory T-cell population performs immune surveillance that keeps the virus latent.

SAP binds to the ITSM of SLAM family receptors including 2B4 and blocks access by inhibitory molecules such as SHP-2 (tyrosine phosphatase), thereby keeping 2B4 signaling in the activating direction. When SAP is deficient, 2B4 signaling is switched in the inhibitory direction by SHP-2, and the cytotoxic capacity of NK cells and CTLs against EBV-infected B cells is markedly reduced. At the same time, SAP is also essential for T-cell-to-T-cell interactions (regulation of follicular helper T cell, Tfh, differentiation), so in SAP deficiency, Tfh cell dysfunction also impairs formation of a long-term EBV-specific B-cell antibody response.

After EBV infection in SAP-deficient patients, infected B cells proliferate without limit while T cells undergo sustained, excessive activation. These hyperactive T cells and histiocytes (macrophages) cause a cytokine storm, and hemophagocytosis, in which histiocytes engulf blood cells (red blood cells, white blood cells, platelets), proceeds in the bone marrow, spleen, liver, and lymph nodes, resulting in HLH. HLH is characterized by persistent high fever, splenomegaly, cytopenia in two or more lineages, hyperferritinemia, and hypertriglyceridemia. If this cytokine storm is not controlled, the patient dies of multiple organ failure.

In XLP2 (XIAP deficiency), loss of the cell-death-inhibiting function of XIAP and impaired NOD2 signaling form a combined mechanism. XIAP is involved in activating NF-κB by ubiquitinating RIP2 kinase in NOD2 receptor signaling, and in XIAP deficiency this process is disrupted, immune regulation in the intestinal mucosa fails, and IBD-like enteritis occurs. In addition, in XIAP-deficient T/NK cells, excessive cell death after activation paradoxically results in immune dysregulation, leading to HLH.

6. Symptoms

The clinical symptoms of XLP vary greatly depending on whether EBV infection has occurred and the type of response that appears on infection, and the spectrum of phenotypes is wide. Within a single patient, several phenotypes may occur sequentially or simultaneously.

Fatal infectious mononucleosis (FIM): the most dramatic manifestation after primary EBV infection. It begins with high fever, sore throat, cervical lymphadenopathy, and hepatosplenomegaly, with increased atypical lymphocytes and elevated liver enzymes. In normal individuals it improves in a self-limited manner, but in XLP patients it deteriorates rapidly and progresses to liver failure, bleeding tendency (DIC), renal failure, and multiple organ failure, leading to death. FIM occurs in about 60-70% of XLP patients and has traditionally been the most frequently reported clinical phenotype.

Hemophagocytic lymphohistiocytosis (HLH): triggered by EBV infection or other viral infections, and in XLP2 (XIAP deficiency) it occurs even without EBV. Findings include high fever (38.5°C or higher, >7 days), splenomegaly, cytopenia (hemoglobin <9 g/dL or platelets <100,000/μL), hyperferritinemia (>500 ng/mL, >10,000 in severe cases), hypertriglyceridemia, low or absent NK cell activity, elevated soluble CD25 (sIL-2Rα), and hemophagocytosis in bone marrow/spleen/lymph nodes. HLH is fatal within days to weeks if not treated immediately upon diagnosis.

Malignant lymphoma: the risk of non-Hodgkin lymphoma (NHL) is very high in XLP patients, and EBV-positive B-cell lymphoma (Burkitt lymphoma-like or diffuse large B-cell lymphoma) is the most common. Lymphoma occurs after EBV infection or subsequently after survival. It favors extranodal sites (gastrointestinal tract, central nervous system, etc.).

Hypogammaglobulinemia: after EBV infection or independently, serum IgG, IgA, and IgM decrease, increasing susceptibility to bacterial infection. This is due to Tfh cell dysfunction and impaired B-cell immune response caused by SAP deficiency. In XLP2 (XIAP deficiency), inflammatory bowel disease (IBD) — Crohn disease-like or ulcerative colitis-like — characteristically accompanies it.

7. Signs

The physical and laboratory signs of XLP differ according to the type of clinical manifestation.

Physical findings: at EBV infection or HLH onset, persistent high fever (38.5°C or higher) is observed and hepatosplenomegaly is palpable. Cervical and axillary lymphadenopathy accompanies it, but in malignant lymphoma the lymph nodes are hard and painless. Jaundice (with liver failure), mucosal bleeding (thrombocytopenia), and edema (hypoalbuminemia) may appear. When the central nervous system is involved, neurological abnormalities (seizures, altered consciousness) occur.

Laboratory findings — HLH diagnostic criteria (HLH-2004): ① fever ≥38.5°C, lasting ≥7 days; ② splenomegaly; ③ cytopenia in two or more lineages (Hb <9 g/dL, platelets <100,000/μL, neutrophils <1,000/μL); ④ hypertriglyceridemia (fasting TG >265 mg/dL) or hypofibrinogenemia (<150 mg/dL); ⑤ hemophagocytosis in bone marrow/spleen/lymph nodes; ⑥ decreased or absent NK cell activity (including degranulation assay); ⑦ serum ferritin >500 ng/mL; ⑧ elevated soluble CD25 (sIL-2Rα) (>2,400 U/mL). The diagnosis is made when 5 or more criteria are met or when genetic HLH (including XLP) is confirmed.

EBV-related serological findings: an abnormal pattern of elevated VCA-IgM, positive EA (early antigen)-IgG, and negative EBNA antibody (which should appear in the convalescent phase in normal individuals but is often not produced in XLP) is characteristic. EBV DNA viremia is quantitatively confirmed by EBV PCR (plasma). SAP protein expression: loss or marked reduction of SAP protein expression in CD4+ T cells, CD8+ T cells, and NK cells is confirmed by flow cytometry. XIAP protein expression: loss of XIAP expression in monocytes and T cells is confirmed (flow cytometry or Western blot).

8. Screening

Because XLP is asymptomatic until EBV infection, systematic screening is possible only when there is a family history. The following screening approaches by situation are recommended.

Boys with a family history: boys born to the mother (confirmed carrier) of a patient with confirmed XLP1 or XLP2 undergo targeted variant analysis of the SH2D1A and XIAP genes immediately after birth. After a variant is confirmed, immune function is evaluated (T/B/NK cell fractions, T-cell function, serum Ig), and EBV serostatus is monitored regularly to detect primary EBV infection early.

Boys who experienced fatal mononucleosis or HLH: when a boy develops severe disease or HLH after EBV infection, a primary HLH-related gene panel test including XLP (SH2D1A, XIAP, PRF1, UNC13D, STXBP2, RAB27A, LYST, AP3B1, STXBP2, etc.) is performed immediately. At the same time, SAP protein expression (flow cytometry) and NK cell degranulation function testing are performed to assess functional deficiency.

Protein expression screening: SAP protein expression (flow cytometry — measuring SAP expression in CD8+ T cells) and XIAP protein expression (measuring XIAP expression in monocytes) can be performed faster than genetic testing and are highly sensitive, so they are useful as initial screening tests. If protein expression is lost, the diagnosis is confirmed by gene sequencing.

EBV exposure monitoring: to detect primary EBV infection early in confirmed XLP patients, EBV VCA IgM and EBV PCR (plasma) are performed regularly (at 6-month to 1-year intervals, or immediately when fever or mononucleosis symptoms occur). Early detection of primary EBV infection is essential for immediate rituximab administration and for establishing an HSCT plan.

9. Diagnosis

The diagnosis of XLP is confirmed by stepwise testing based on clinical suspicion.

Step 1: clinical evaluation and HLH diagnosis: evaluate the HLH-2004 criteria (whether 5 or more are met) and perform EBV-related serology (VCA, EA, EBNA IgM/IgG)/PCR testing. In boys with fatal mononucleosis or HLH, XLP is considered as the first-priority differential diagnosis.

Step 2: protein expression testing: measure SAP protein expression (in CD8+ T cells or CD4+ T cells) by flow cytometry. Loss or marked reduction of SAP expression is strong evidence of XLP1. XIAP protein expression in monocytes is also measured at the same time. This test can be performed even in the acute phase, and results can be obtained quickly.

Step 3: gene sequencing: confirm the pathogenic variant by Sanger sequencing or an NGS panel test of the SH2D1A gene (exons 1-4) and the XIAP gene (exons 1-7). Even when no variant is detected, if clinical and protein expression findings are clear, clinical XLP can be diagnosed.

Step 4: adjunctive tests: perform bone marrow biopsy (confirming hemophagocytic histiocytes), serum ferritin, TG, and fibrinogen, sCD25, NK cell degranulation function tests (CD107a expression, perforin/granzyme expression), and quantitative serum immunoglobulins (assessing hypogammaglobulinemia).

Differential diagnosis: differentiation is needed from familial HLH (FHL, variants of PRF1/UNC13D/STXBP2/RAB27A, etc.), EBV-associated HLH (EBV infection in immunocompetent individuals), acquired immunodeficiency syndrome (HIV), and other XLP-like syndromes (ITK deficiency, CD27 deficiency, MAGT1 deficiency, CARD11 variants).

10. Treatment

Treatment of XLP can be broadly divided into acute-phase treatment of HLH, preemptive blocking of EBV infection, and cure using HSCT.

Acute-phase treatment of HLH (HLH-2004 protocol): combination therapy of dexamethasone and etoposide is started immediately upon HLH diagnosis, and after the initial 8 weeks of treatment it continues into maintenance treatment. Dexamethasone suppresses hyperactivation of T cells and histiocytes, and etoposide selectively eliminates activated lymphocytes and histiocytes. Cyclosporine A is sometimes added. Because EBV-positive B cells are the main stimulus of HLH in XLP, administration of rituximab (anti-CD20 monoclonal antibody) is effective: it eliminates EBV-infected B cells and blocks the cause of the cytokine storm. Rituximab is used alone or in combination with the HLH-2004 protocol.

Curative treatment: HSCT: HSCT is currently the only curative therapy for XLP. The best prognosis is seen when HSCT is performed before EBV infection (before HLH onset). Because survival is low when HSCT is performed after EBV infection or HLH onset, it is recommended to plan HSCT as soon as possible after the diagnosis is confirmed. Transplantation from an HLA-matched sibling donor is ideal, and unrelated donor transplantation is also performed. Reduced-intensity conditioning (RIC) is preferred, but standard-intensity conditioning may be needed when active HLH or lymphoma is present. Because patients with XIAP deficiency (XLP2) develop recurrent HLH even without EBV infection, early HSCT is emphasized even more.

Supportive treatment: regular IVIG administration in patients with confirmed hypogammaglobulinemia. Use of EBV-negative or leukocyte-filtered blood products to block EBV exposure. Prophylactic antibacterial, antifungal, and antiviral agents. Live vaccines contraindicated. IBD management in XLP2 (steroids, biologics).

11. Prognosis

The prognosis of XLP differs sharply depending on the timing of diagnosis and whether EBV infection has occurred. When treatment is not received or is delayed after EBV infection, mortality reaches 70-100%. Historically, most patients died in the first episode after primary EBV infection.

Prognosis after HSCT: when HSCT is performed before EBV infection, 5-year survival is reported as 70-85% or higher. HSCT after EBV infection or HLH onset carries a high risk of conditioning-related death and a low transplant success rate, so survival falls to about 50%. Therefore early diagnosis → early transplantation is the key to determining prognosis. Since the introduction of rituximab, acute-phase mortality of HLH has decreased somewhat, increasing the possibility of bridging to HSCT.

Prognosis when lymphoma develops: when EBV-positive B-cell lymphoma develops, a strategy of standard chemotherapy followed by HSCT is recommended, and long-term survival is possible when transplantation is performed after complete remission of the lymphoma. However, the occurrence of lymphoma itself is a factor that worsens prognosis.

Prognosis of XIAP deficiency (XLP2): prognosis is good with early HSCT, but long-term management of IBD is needed. Because EBV-negative spontaneous HLH recurs, HSCT is planned early even before EBV infection. IBD often improves or resolves after HSCT.

12. Prevention

Prevention of XLP consists of genetic prevention, blocking EBV exposure, and early HSCT.

Primary prevention: through genetic counseling, the risk (50%) of giving birth to an affected boy is explained to carrier women, and preimplantation genetic testing (PGT) or prenatal diagnosis (CVS/amniocentesis) is recommended. Carrier women are advised to receive counseling on the X-linked mode of inheritance and to consult a geneticist when planning pregnancy.

Secondary prevention: in diagnosed XLP patients, HSCT before primary EBV infection is the best preventive measure. To minimize EBV exposure, EBV-positive blood products are avoided (EBV-negative or leukocyte-filtered products are used), and hygiene is rigorously managed in environments with risk of EBV infection such as school. Hypogammaglobulinemia is prevented by regular IVIG administration. Primary EBV infection is detected early through regular monitoring of EBV VCA IgM and EBV PCR. If primary EBV infection is confirmed, immediate rituximab administration is considered and an urgent HSCT plan is established.

Tertiary prevention: infection prophylaxis (prophylactic anti-infectives, IVIG) maintained until immune reconstitution is complete after HSCT. Regular checkups to monitor for lymphoma. Long-term IBD management in XLP2. Screening of female carriers and other male family members is recommended. Psychological and social support and linkage to rare disease patient networks.


13. References

  1. Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). The Lancet. 1975;1(7913):935–940. DOI: 10.1016/S0140-6736(75)92109-2. PMID: 48809.

  2. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genetics. 1998;20(2):129–135. DOI: 10.1038/2424. PMID: 9771704.

  3. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proceedings of the National Academy of Sciences USA. 1998;95(23):13765–13770. DOI: 10.1073/pnas.95.23.13765. PMID: 9811876.

  4. Rigaud S, Fondanèche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444(7115):110–114. DOI: 10.1038/nature05257. PMID: 17080092.

  5. Marsh RA, Bleesing JJ, Chandrakasan S, et al. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biology of Blood and Marrow Transplantation. 2014;20(10):1641–1645. DOI: 10.1016/j.bbmt.2014.06.003. PMID: 24946228.

  6. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer. 2007;48(2):124–131. DOI: 10.1002/pbc.21039. PMID: 16937360.

  7. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010;116(18):3398–3408. DOI: 10.1182/blood-2010-03-274886. PMID: 20660790.

  8. Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53–62. DOI: 10.1182/blood-2010-06-284935. PMID: 20926771.

  9. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.

  10. Ammann S, Elling R, Gyrd-Hansen M, et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clinical & Experimental Immunology. 2014;176(3):394–400. DOI: 10.1111/cei.12306. PMID: 24521429.